Promising results were also obtained with PRI-724/C-82 compound, a C-EBP/β-catenin inhibitor, on different models of leukemia (including T-ALL, AML and CML) also in the context of drug resistant cells (37, 65). Here, CEBPA is linked to acute lymphoblastic leukemia.